Abstract
The compound 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a potent inhibitor of a number of viruses in vitro, such as human immunodeficiency virus types 1 and 2, herpes simplex virus types 1 and 2, hepatitis B virus, cytomegalovirus, and Epstein-Barr virus. PMEA also proved to be effective in vivo against feline immunodeficiency virus in cats and simian immunodeficiency virus in rhesus monkeys. In an open, non-placebo-controlled trial, the safety of weekly doses of PMEA in 10 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex was studied for a period of 11 weeks. CD4+ T-Cell counts at baseline were between 10 and 450/mm3. The drug was administered intravenously at a dose of 1000 mg. No serious side-effects were seen. On one occasion one patient showed alanine aminotransferase and aspartate aminotransferase levels 5 times higher than the upper limit of normal and another patient showed on one occasion aspartate aminotransferase levels 5 times higher than the upper limit of normal. In another patient serum amalyse levels increased, on one occasion 1.5 times above the upper limit of normal. An improvement in general well-being was reported by all patients. For patients with a CD4+ T-cell count > 100/mm3 at baseline, the CD4+ T-cell count increased from a mean of 283/mm3 at baseline to a mean of 448/mm3 at the end of the study. Repeat infusions of PMEA at a dose of 1000 mg were safe and well tolerated. Our results suggest that PMEA, administrated according to this treatment schedule, may be effective in treating patients with human immunodeficiency virus infection.
Similar content being viewed by others
References
Fischl M, Richman D, Grieco M, Gottlieb M, Volberding P, Laskin O, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185–91.
Lambert JS, Seidlin M, Reichman R, Plank C, Laverty M, Morse G, et al. 2′,3′-Dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1340–5.
Collier A, Coombs R, Fischl M, Skolnik P, Northfelt D, Boutin P, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786–93.
Meng T, Fischl M, Boota A, Spector SA, Bennett D, Bassiakos Y, et al. Combination therapy with zidovudine and dide-oxycytidine in patients with advanced human immuno-deficiency virus infection: a phase I/II study. Ann Intern Med 1992;116:13–20.
Richman D, Fisch M, Grieco M, Gottlieb M, Volberding P, Loskin O, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192–7.
De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464–7.
Balzarini J, Perno C-F, Schols D, de Clercq E. Activity of acyclic nucleoside phosphonates analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun 1991;178:329–35.
Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, et al. Phosphonylmethoxyethyl purine derivatives a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988;32:1025–30.
Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holý A, Pauwels R, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332–6.
Heijtink R, de Wilde G, Kruining J, Berk L, Balzarini J, De Clercq E, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 21:141–53.
Heijtink R, Kruining J, de Wilde G, Balzarini J, de Clercq E, Schalm S. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994;38:2180–2.
Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, de Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991;35:394–7.
Cerny J, Foster S, Cheng Y. Cell-protecting effect against herpes simplex virus-1 and cellular metabolism of 9-(2-phosphonylmethoxyethyl)adenine in HeLa S3 cells. Mol Pharmacol 1991;42:537–44.
De Clercq E, Holý A, Rosenberg I. Efficacy of phosphonyl-methoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother 1989;33:185–91.
Gangemi J, Cozens RM, de Clercq E, Balzarini J, Hochkeppel H. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 1989;33:1864–8.
Vonka V, Anisimova E, Cerny J, Holý A, Rosenberg I, Votruba I. Properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) resistant herpes simplex type 1 virus. Antiviral Res 1990;14:117–21.
Lin J, de Clercq E, Pagano JS. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother 1987;31:1431–3.
De Castro L, Kern E, de Clercq E, Ghaffar A, Mayer E, Vogt P, et al. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res 1991;16:101–14.
Balzarini J, Naesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holý A, et al. 9-(2-Phosphonomethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991;5:21–8.
Egberink H, Borst M, Niphuis H, Balzarini J, Neu H, Schellekens H, et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 1990;87:3087–91.
Hartmann K, Donath A, Beer B, Egberink H, Horzenik M, Lutz H, et al. Use of two virustacia (AZT, PMEA) in treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167–75.
Tsai C, Follis K, Grant R, Sabo A, Nolte R, Bartz C, et al. Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques. J Med Primatol 1994;23:175–83.
Merta A, Vesely I, Votruba I, Rosenberg I, Holý A. Phosphorylation of acyclic nucleotide analogues HPMPA and PMEA in L210 mouse leukemic cell extracts. Neoplasma 1990;37:111–20.
Balzarini J, Hao Z, Herdewijn P, Johns DG, de Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxy)ethyladenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991;88:1499–503.
Naessens L, Balzarini J, de Clercq E. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid with fluorescence detection. Clin Chem 1992;38:480–5.
Russell JW, Marrero D, Whiterock VJ, Klunk LJ, Starrett JE. Determination of 9-(2-phosphonylmethoxy)ethyladenine in rat urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991;572:321–6.
Del Gobbo V, Foli A, Balzarini J, de Clercq E, Balestra E, Viliani N, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991;16:65–75.
Caliò R, Viliani N, Balestra E, Sesa F, Holý A, Balzarini J, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23:77–89.
Villani N, Caliò R, Balestra E, Balzarini J, de Clercq E, Fabrizi E, et al. 9-(2-Phosphonomethoxyethyl)adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res 1994;25:81–9.
Yang H, Datema R. Prolonged and potent therapeutic and prophylactic effects of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine against herpes simplex virus type 2 infections in mice. Antimicrob Agents Chemother 1991;35:1596–600.
Neyts J, Balzarini J, Naesens L, de Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J Med Virol 1992;37:61–71.
Soike K, Huang J-Y, Bohm R, Hitchcock M, Martin JC. Evaluation of infrequent dosing regimens with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res 1991;16:17–28.
Balzarini J, Naesens L, de Clercq E. Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine in vivo increases when it is less frequently administered. Int J Cancer 1990;46:337–40.
Naessens L, Balzarini J, de Clercq E. Single dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEADAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991;16:53–64.
Holý A, Rosenberg I. Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 1987;2:2801–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arends, S., van Halteren, E., Kamp, W. et al. Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection. Pharm World Sci 18, 30–34 (1996). https://doi.org/10.1007/BF00449687
Issue Date:
DOI: https://doi.org/10.1007/BF00449687